Transcriptomics

Dataset Information

0

Microarray analysis of correlates of vaccine immunogenecity following ALVAC vaccination in NHP in Study 36


ABSTRACT: The RV144 HIV vaccine trial remains the only study to demonstrate significant protection from future HIV-1 acquisition. One of the key components of the RV144 vaccine was the use of the canarypox vector ALVAC as the priming component. Since AIDSVAX, the booster component, alone failed to provide protection we hypothesized that the ALVAC prime contributed significantly to the generation of protection. To test this, we designed a NHP immunogenicity trial to mechanistically link ALVAC vaccination with the magnitude of V1V2 titers, the most significant immune correlate of reduced HIV-1 acquisition in RV144. Our objective was to use a systems biology approach to identify the transcription factors, target genes and immune pathways which were being induced by ALVAC vaccination and associated with higher V1V2 titers. We identified the transcription factor CREB1 and its target genes as rapidly induced by ALVAC in multiple immune subsets and that CREB1 drives the expression and activation of a network of other TFs which are critical for modulating immune responses. Pathways induced by this ALVAC-CREB1 axis include lymphocyte/leukocyte migration, lymphocyte differentiation, antigen processing and presentation, T cell co-stimulation and cytokine signaling.

ORGANISM(S): Homo sapiens Macaca mulatta

PROVIDER: GSE180677 | GEO | 2021/07/26

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2021-07-25 | GSE180748 | GEO
2021-07-25 | GSE180747 | GEO
2021-03-17 | GSE164366 | GEO
2019-02-15 | GSE103733 | GEO
2019-02-15 | GSE103671 | GEO
| PRJNA406921 | ENA
2021-08-13 | GSE181996 | GEO
| PRJNA749324 | ENA
2023-12-18 | GSE246866 | GEO
2023-01-06 | GSE188575 | GEO